Aims: Childhood attention-deficit/hyperactivity disorder (ADHD) frequently persists into adulthood and continues to impair health-related quality of life (HRQL). Thus, it is important to have validated symptom and HRQL measures for assessing treatment outcomes in this population. The purpose of the current analysis was to assess test-retest reliability of two measures designed specifically for adults with ADHD: the Adult ADHD Self-Report Screener (ASRS) and the Adult ADHD Quality of Life Measure (AAQoL). Methods: Data were collected at a US clinic specializing in the treatment of adult ADHD. Patients completed the ASRS (six-item ADHD symptom screening version) and the AAQoL (a 29-item condition-specific HRQL measure) at two visits, two weeks apart. At the second visit, patients also completed a measure of symptom stability so that test-retest reliability could be examined in the stable population. Test-retest reliability was examined through intraclass correlations (ICC) and t-tests comparing scores from the two visits. Results: A total of 74 participants were enrolled (62.2% male; mean age = 38.6 years), and 43 of these participants attended both visits and were stable between visits (65.1% male; mean age = 39.3 years). The ICC assessing the association between Visit 1 and Visit 2 ASRS scores was 0.86, and the ICCs for the AAQoL subscales were 0.88 (Life Productivity), 0.75 (Psychological Health), 0.74 (Life Outlook), 0.78 (Relationships), and 0.86 (total score). The t-tests found no statistically significant differences between Visit 1 and Visit 2 scores for the ASRS or AAQoL. Conclusions: The ASRS and AAQoL demonstrated good test-retest reliability. Findings add to previous results suggesting that these instruments are useful outcome measures for treatments of ADHD in adults. (J. of Att. Dis. 2011; 15(7) 557-563)
AdlerL. A.SpencerT.FaraoneS. V.KesslerR. C.HowesM. J.BiedermanJ.SecnikK. (2006). Validity of pilot Adult ADHD Self-Report Scale (ASRS) to rate adult ADHD symptoms. Annals of Clinical Psychiatry, 18, 145-148.
2.
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: American Psychiatric Press.
3.
BiedermanJ.FaraoneS. V.SpencerT. J.MickE.MonuteauxM. C.AleardiM. (2006). Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community. Journal of Clinical Psychiatry, 67, 524-540.
4.
BiedermanJ.MonuteauxM. C.MickE.SpencerT.WilensT. E.SilvaJ. M.. . . StephenV. F. (2006). Young adult outcome of attention deficit hyperactivity disorder: A controlled 10-year follow-up study. Psychological Medicine, 36, 167-179.
5.
BrodM.PerwienA.AdlerL.SpencerT.JohnstonJ. (2005). Conceptualization and assessment of quality of life for adults with attention-deficit/hyperactivity disorder. Primary Psychiatry, 12, 58-64.
6.
BrodM.JohnstonJ.AbleS.SwindleR. (2006). Validation of the Adult Attention-Deficit/Hyperactivity Disorder Quality-of-Life Scale (AAQoL): A disease-specific quality-of-life measure. Quality of Life Research, 15, 117-129.
7.
DavidsonM. A. (2008). ADHD in adults: A review of the literature. Journal of Attention Disorders, 11, 628-641.
8.
DeyoR. A.DiehrP.PatrickD. L. (1991). Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Controlled Clinical Trials, 12(Suppl. 4), 142S-158S.
9.
EakinL.MindeK.HechtmanL.OchsE.KraneE.BouffardR.LooperK. (2004). The marital and family functioning of adults with ADHD and their spouses. Journal of Attention Disorders, 8, 1-10.
10.
FaraoneS. V.BiedermanJ. (2005). What is the prevalence of adult ADHD? Results of a population screen of 966 adults. Journal of Attention Disorders, 9, 384-391.
11.
Food Drug Administration (FDA). (2006). Guidance for industry—Patient-reported outcome measures: Use in medical product development to support labeling claims. Silver Spring, MD: FDA; December2009.
12.
FriedmanS. R.RapportL. J.LumleyM.TzelepisA.VanVoorhisA.StettnerL.KakaatiL. (2003). Aspects of social and emotional competence in adult attention-deficit/hyperactivity disorder. Neuropsychology, 17, 50-58.
13.
GuyattG. H.FeenyD. H.PatrickD. L. (1993). Measuring health-related quality of life. Annals of Internal Medicine, 118, 622-629.
14.
JaeschkeR.SingerJ.GuyattG. H. (1989). Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials, 10, 407-415.
15.
KesslerR. C.AdlerL.AmesM.BarkleyR. A.BirnbaumH.GreenbergP.UstünT. B. (2005). The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. Journal of Occupational and Environmental Medicine, 47, 565-572.
16.
KesslerR. C.AdlerL. A.BarkleyR.BiedermanJ.ConnersC. K.FaraoneS. V.. . . ZaslavskyA. M. (2005). Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: Results from the national comorbidity survey replication. Biological Psychiatry, 57, 1442-1451.
17.
KesslerR. C.AdlerL. A.GruberM. J.SarawateC. A.SpencerT.Van BruntD. L. (2007). Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan members. International Journal of Methods in Psychiatric Research, 16, 52-65.
18.
KolarD.KellerA.GolfinopoulosM.CumynL.SyerC.HechtmanL. (2008). Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatric Disease and Treatment, 4, 389-403.
19.
LeidyN. K.RevickiD. A.GenesteB. (1999). Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value in Health, 2, 113-127.
20.
MannuzzaS.KleinR. G.MoultonJ. L.III. (2003). Persistence of attention-deficit/hyperactivity disorder into adulthood: What have we learned from the prospective follow-up studies?Journal of Attention Disorders, 7, 93-100.
21.
MatzaL. S.JohnstonJ. A.FariesD. E.MalleyK. G.BrodM. (2007). Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL). Quality of Life Research, 16, 1511-1520.
22.
PatrickD. L.BurkeL. B.PowersJ. H.ScottJ. A.RockE. P.DawishaS.. . . KennedyD. L. (2007). Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health, 10(Suppl. 2), S125-137.
23.
SafrenS. A.SprichS.ChulvickS.OttoM. W. (2004). Psychosocial treatments for adults with attention-deficit/hyperactivity disorder. Psychiatric Clinics of North America, 27, 349-360.
24.
Scientific Advisory Committee of the Medical Outcomes Trust. (2002). Assessing health status and quality-of-life instruments: Attributes and review criteria. Quality of Life Research, 11, 193-205.
25.
SimpsonD.PloskerG. L. (2004). Atomoxetine: A review of its use in adults with attention deficit hyperactivity disorder. Drugs, 64, 205-222.
26.
SpencerT.BiedermanJ.WilensT. (2004a). Nonstimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatric Clinics of North America, 27, 373-383.
27.
SpencerT.BiedermanJ.WilensT. (2004b). Stimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatric Clinics of North America, 27, 361-372.
28.
WilensT. E. (2008). Pharmacotherapy of ADHD in Adults. CNS Spectrums, 13(Suppl. 8), 11-13.
